Adverum Biotechnologies Inc (ADVM)

Schlusskurs vom Vortag:

$9.19

Offen:

$9.29

24-Stunden-Volumen:

800.36K

Marktkapitalisierung:

$196.66M

Einnahmen:

-

Nettoeinkommen (Verlust:

$-117.17M

KGV:

-7.1654

EPS:

-1.33

Netto-Cashflow:

$-91.71M

1W Leistung:

-15.96%

1M Leistung:

-32.60%

6M Leistung:

+903.26%

1J Leistung:

+1,116%

1-Tages-Spanne:

$8.76

$9.964

52-Wochen-Spanne:

$0.721

$17.65

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Firmenname

Adverum Biotechnologies Inc

Sektor

Healthcare (1203)

Branche

Biotechnology (688)

Telefon

650-272-6269

Adresse

1035 O'Brien Drive, Suite A, Menlo Park, CA

Mitarbeiter

96

Twitter

@adverumbio

Nächster Verdiensttermin

2024-05-09

Neueste SEC-Einreichungen

ADVM's Discussions on Twitter

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-07-07	Hochstufung	Truist	Hold → Buy
2021-07-23	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2021-05-03	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-04-29	Herabstufung	Chardan Capital Markets	Buy → Neutral
2021-04-29	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-04-29	Herabstufung	Truist	Buy → Hold
2020-12-16	Eingeleitet	UBS	Neutral
2020-11-12	Hochstufung	Raymond James	Underperform → Mkt Perform
2020-06-26	Herabstufung	Raymond James	Mkt Perform → Underperform
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-05-05	Hochstufung	SunTrust	Hold → Buy
2020-04-28	Eingeleitet	Goldman	Buy
2020-03-16	Eingeleitet	SVB Leerink	Outperform
2020-02-10	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-02-10	Hochstufung	Chardan Capital Markets	Neutral → Buy
2019-10-15	Bestätigt	Chardan Capital Markets	Neutral
2019-09-13	Bestätigt	Chardan Capital Markets	Neutral
2019-06-14	Fortgesetzt	Raymond James	Mkt Perform
2018-11-02	Herabstufung	Raymond James	Outperform → Mkt Perform
2018-11-02	Herabstufung	SunTrust	Buy → Hold
2018-09-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-08-30	Eingeleitet	SunTrust	Buy
2018-02-15	Fortgesetzt	Piper Jaffray	Overweight
2017-10-12	Eingeleitet	Raymond James	Outperform

Alle ansehen

Adverum Biotechnologies Inc Aktie (ADVM) Neueste Nachrichten

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

GlobeNewswire Inc.

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Zacks Investment Research

Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

Zacks Investment Research

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

Zacks Investment Research

How Adverum (ADVM) Stock Stands Out in a Strong Industry

Zacks Investment Research

Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround

Zacks Investment Research

Finanzdaten der Adverum Biotechnologies Inc-Aktie (ADVM)

Adverum Biotechnologies Inc (ADVM) Nettogewinn 2024

Adverum Biotechnologies Inc (ADVM) Free Cashflow 2024

Adverum Biotechnologies Inc (ADVM) Gewinn je Aktie 2024

Adverum Biotechnologies Inc-Aktie (ADVM) Insiderhandel